开云app官网登录入口网页版-官方正版

#S-1#

72篇内容 | 1894人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1477894, encodeId=dafb14e7894dd, content=<a href='/topic/show?id=944315e85c0' target=_blank style='color:#2F92EE;'>#S-1#</a>, objectTitle=EmPHasis-10 球囊血管成形术后慢性血栓栓塞性肺动脉高压的健康相关生活质量和运动能力, objectType=article, longId=737811, objectId=2777e37811af, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2777e37811af, replyNumber=0, likeNumber=75, createdTime=2022-09-06, rootId=0, userName=ms3117646317107274, userId=a6477383481, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2777e37811af, moduleTitle=EmPHasis-10 球囊血管成形术后慢性血栓栓塞性肺动脉高压的健康相关生活质量和运动能力, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=2777e37811af)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1477893, encodeId=398b14e789335, content=<a href='/topic/show?id=944315e85c0' target=_blank style='color:#2F92EE;'>#S-1#</a>, objectTitle=J Autoimmunity：ETS-1通过上调CIRBP促进炎症性肠病中Th1细胞介导的黏膜炎症, objectType=article, longId=735821, objectId=5ea7e358217a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5ea7e358217a, replyNumber=0, likeNumber=92, createdTime=2022-08-15, rootId=0, userName=ms3117646317107274, userId=a6477383481, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5ea7e358217a, moduleTitle=J Autoimmunity：ETS-1通过上调CIRBP促进炎症性肠病中Th1细胞介导的黏膜炎症, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=5ea7e358217a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1477892, encodeId=109814e78925d, content=<a href='/topic/show?id=944315e85c0' target=_blank style='color:#2F92EE;'>#S-1#</a>, objectTitle=Oncologist: Apatinib（阿帕替尼）与S-1联合一线治疗晚期胃癌疗效和安全性, objectType=article, longId=221378, objectId=de1e2213e8db, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=de1e2213e8db, replyNumber=0, likeNumber=86, createdTime=2021-12-02, rootId=0, userName=ms3117646317107274, userId=a6477383481, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=de1e2213e8db, moduleTitle=Oncologist: Apatinib（阿帕替尼）与S-1联合一线治疗晚期胃癌疗效和安全性, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=de1e2213e8db)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1477891, encodeId=1c0614e78913e, content=<a href='/topic/show?id=944315e85c0' target=_blank style='color:#2F92EE;'>#S-1#</a>, objectTitle=Oncologist: Anlotinib（安罗替尼）联合S-1三线或后线治疗晚期NSCLC患者的疗效和安全性：II期临床研究, objectType=article, longId=221301, objectId=e3df221301c8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e3df221301c8, replyNumber=0, likeNumber=102, createdTime=2021-12-01, rootId=0, userName=ms3117646317107274, userId=a6477383481, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e3df221301c8, moduleTitle=Oncologist: Anlotinib（安罗替尼）联合S-1三线或后线治疗晚期NSCLC患者的疗效和安全性：II期临床研究, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=e3df221301c8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1477890, encodeId=6f9e14e78904e, content=<a href='/topic/show?id=944315e85c0' target=_blank style='color:#2F92EE;'>#S-1#</a>, objectTitle=J Thorac Oncol：Aumolertinib(HS-10296)治疗EGFR-T790M+晚期NSCLC患者的疗效和安全性：APOLLO研究, objectType=article, longId=221184, objectId=7716221184e3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7716221184e3, replyNumber=0, likeNumber=64, createdTime=2021-11-29, rootId=0, userName=ms3117646317107274, userId=a6477383481, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7716221184e3, moduleTitle=J Thorac Oncol：Aumolertinib(HS-10296)治疗EGFR-T790M+晚期NSCLC患者的疗效和安全性：APOLLO研究, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=7716221184e3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1477889, encodeId=97a314e788959, content=<a href='/topic/show?id=944315e85c0' target=_blank style='color:#2F92EE;'>#S-1#</a>, objectTitle=Eur J Cancer：3期| 改良版FOLFIRINOX vs S-1方案二线治疗吉西他滨难治性转移性胰腺癌的疗效, objectType=article, longId=216768, objectId=ddae216e6887, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ddae216e6887, replyNumber=0, likeNumber=87, createdTime=2021-09-08, rootId=0, userName=ms3117646317107274, userId=a6477383481, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ddae216e6887, moduleTitle=Eur J Cancer：3期| 改良版FOLFIRINOX vs S-1方案二线治疗吉西他滨难治性转移性胰腺癌的疗效, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=ddae216e6887)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1477888, encodeId=d8d414e788891, content=<a href='/topic/show?id=944315e85c0' target=_blank style='color:#2F92EE;'>#S-1#</a>, objectTitle=LANCET ONCOL：围手术期或术后辅助奥沙利铂联合S-1 vs术后辅助奥沙利铂联合卡培他滨在接受D2胃切除术的局部进展期胃或胃食管结合部腺癌患者的疗效和安全性(RESOLVE): 一项开放标签、优效性和非劣效的3期随机对照研究, objectType=article, longId=214070, objectId=468d2140e0fd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=468d2140e0fd, replyNumber=0, likeNumber=51, createdTime=2021-07-13, rootId=0, userName=ms3117646317107274, userId=a6477383481, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=468d2140e0fd, moduleTitle=LANCET ONCOL：围手术期或术后辅助奥沙利铂联合S-1 vs术后辅助奥沙利铂联合卡培他滨在接受D2胃切除术的局部进展期胃或胃食管结合部腺癌患者的疗效和安全性(RESOLVE): 一项开放标签、优效性和非劣效的3期随机对照研究, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=468d2140e0fd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1477887, encodeId=924a14e78875b, content=<a href='/topic/show?id=944315e85c0' target=_blank style='color:#2F92EE;'>#S-1#</a>, objectTitle=Cancers：放疗联合S-1治疗头颈部肿瘤的的疗效和安全性：来自Meta分析, objectType=article, longId=212730, objectId=dfbe212e30d5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dfbe212e30d5, replyNumber=0, likeNumber=87, createdTime=2021-06-16, rootId=0, userName=ms3117646317107274, userId=a6477383481, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dfbe212e30d5, moduleTitle=Cancers：放疗联合S-1治疗头颈部肿瘤的的疗效和安全性：来自Meta分析, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=dfbe212e30d5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1477886, encodeId=469e14e7886a3, content=<a href='/topic/show?id=944315e85c0' target=_blank style='color:#2F92EE;'>#S-1#</a>, objectTitle=Nutrients：嗜酸乳杆菌DDS-1和乳酸双歧杆菌UABla-12可改善IBS患者的腹痛严重程度和症状, objectType=article, longId=206485, objectId=2a0820648539, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2a0820648539, replyNumber=0, likeNumber=77, createdTime=2021-02-01, rootId=0, userName=ms3117646317107274, userId=a6477383481, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2a0820648539, moduleTitle=Nutrients：嗜酸乳杆菌DDS-1和乳酸双歧杆菌UABla-12可改善IBS患者的腹痛严重程度和症状, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=2a0820648539)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1477885, encodeId=cfb714e788522, content=<a href='/topic/show?id=944315e85c0' target=_blank style='color:#2F92EE;'>#S-1#</a>, objectTitle=Lancet oncol：S-1辅助治疗联合内分泌治疗用于ER+Her2-原发性侵袭性乳腺癌的疗效和安全性, objectType=article, longId=205423, objectId=1d0e20542306, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1d0e20542306, replyNumber=0, likeNumber=61, createdTime=2021-01-08, rootId=0, userName=ms3117646317107274, userId=a6477383481, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1d0e20542306, moduleTitle=Lancet oncol：S-1辅助治疗联合内分泌治疗用于ER+Her2-原发性侵袭性乳腺癌的疗效和安全性, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=1d0e20542306)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1477884, encodeId=88a114e788478, content=<a href='/topic/show?id=944315e85c0' target=_blank style='color:#2F92EE;'>#S-1#</a>, objectTitle=Br J Cancer：IRS-1介导ER+乳腺癌中PR驱动的干细胞性和内分泌抗性, objectType=article, longId=203364, objectId=8909203364df, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8909203364df, replyNumber=0, likeNumber=68, createdTime=2020-11-15, rootId=0, userName=ms3117646317107274, userId=a6477383481, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8909203364df, moduleTitle=Br J Cancer：IRS-1介导ER+乳腺癌中PR驱动的干细胞性和内分泌抗性, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=8909203364df)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1477883, encodeId=c0b914e7883d6, content=<a href='/topic/show?id=944315e85c0' target=_blank style='color:#2F92EE;'>#S-1#</a>, objectTitle=SLEEP 2020：AXS-12（reboxetine）治疗嗜睡症，II期试验结果即将揭晓, objectType=article, longId=200039, objectId=e77f200039b3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e77f200039b3, replyNumber=0, likeNumber=134, createdTime=2020-08-31, rootId=0, userName=ms3117646317107274, userId=a6477383481, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e77f200039b3, moduleTitle=SLEEP 2020：AXS-12（reboxetine）治疗嗜睡症，II期试验结果即将揭晓, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=e77f200039b3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1477882, encodeId=086914e7882f8, content=<a href='/topic/show?id=944315e85c0' target=_blank style='color:#2F92EE;'>#S-1#</a>, objectTitle=靶向TROP2治疗药物DS-1062是NSCLC和乳腺癌的新星？, objectType=article, longId=199024, objectId=524f199024ef, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=524f199024ef, replyNumber=0, likeNumber=76, createdTime=2020-08-10, rootId=0, userName=ms3117646317107274, userId=a6477383481, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=524f199024ef, moduleTitle=靶向TROP2治疗药物DS-1062是NSCLC和乳腺癌的新星？, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=524f199024ef)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1477881, encodeId=8bf714e788117, content=<a href='/topic/show?id=944315e85c0' target=_blank style='color:#2F92EE;'>#S-1#</a>, objectTitle=抗体药物偶联物DS-1062研究范围被扩大，治疗晚期或转移性三阴性乳腺癌, objectType=article, longId=196920, objectId=36881969209a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=36881969209a, replyNumber=0, likeNumber=71, createdTime=2020-07-04, rootId=0, userName=ms3117646317107274, userId=a6477383481, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=36881969209a, moduleTitle=抗体药物偶联物DS-1062研究范围被扩大，治疗晚期或转移性三阴性乳腺癌, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=36881969209a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1477880, encodeId=48bc14e788031, content=<a href='/topic/show?id=944315e85c0' target=_blank style='color:#2F92EE;'>#S-1#</a>, objectTitle=Cell Death Dis：mPGES-1/PGE2/MTDH轴调控T-ALL细胞生长, objectType=article, longId=192540, objectId=50e4192540bc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=50e4192540bc, replyNumber=0, likeNumber=60, createdTime=2020-04-21, rootId=0, userName=ms3117646317107274, userId=a6477383481, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=50e4192540bc, moduleTitle=Cell Death Dis：mPGES-1/PGE2/MTDH轴调控T-ALL细胞生长, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=50e4192540bc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1477879, encodeId=2ab214e787991, content=<a href='/topic/show?id=944315e85c0' target=_blank style='color:#2F92EE;'>#S-1#</a>, objectTitle=Lancet oncol：TAS-102联合贝伐珠单抗可明显延长难治性转移性结直肠癌的无进展存活期, objectType=article, longId=187111, objectId=646618e11101, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=646618e11101, replyNumber=0, likeNumber=103, createdTime=2020-02-03, rootId=0, userName=ms3117646317107274, userId=a6477383481, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=646618e11101, moduleTitle=Lancet oncol：TAS-102联合贝伐珠单抗可明显延长难治性转移性结直肠癌的无进展存活期, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=646618e11101)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1477878, encodeId=91bb14e787868, content=<a href='/topic/show?id=944315e85c0' target=_blank style='color:#2F92EE;'>#S-1#</a>, objectTitle=ASCO 2020年度胃肠道癌专题讨论会：LONSURF和Futibatinib（TAS-120）的全新数据, objectType=article, longId=186810, objectId=ee3118681049, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ee3118681049, replyNumber=0, likeNumber=86, createdTime=2020-01-29, rootId=0, userName=ms3117646317107274, userId=a6477383481, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ee3118681049, moduleTitle=ASCO 2020年度胃肠道癌专题讨论会：LONSURF和Futibatinib（TAS-120）的全新数据, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=ee3118681049)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1477877, encodeId=a2be14e787735, content=<a href='/topic/show?id=944315e85c0' target=_blank style='color:#2F92EE;'>#S-1#</a>, objectTitle=Sci tranl med：用GCase小分子调节剂（S-181）治疗帕金森病, objectType=article, longId=181824, objectId=32f218182434, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=32f218182434, replyNumber=0, likeNumber=71, createdTime=2019-10-25, rootId=0, userName=ms3117646317107274, userId=a6477383481, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=32f218182434, moduleTitle=Sci tranl med：用GCase小分子调节剂（S-181）治疗帕金森病, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=32f218182434)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1477876, encodeId=c35614e7876f2, content=<a href='/topic/show?id=944315e85c0' target=_blank style='color:#2F92EE;'>#S-1#</a>, objectTitle=鞘内注射AVXS-101治疗2型SMA患者的STRONG试验取得阳性结果, objectType=article, longId=180634, objectId=8340180634bd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8340180634bd, replyNumber=0, likeNumber=85, createdTime=2019-10-09, rootId=0, userName=ms3117646317107274, userId=a6477383481, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8340180634bd, moduleTitle=鞘内注射AVXS-101治疗2型SMA患者的STRONG试验取得阳性结果, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=8340180634bd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1477875, encodeId=690314e78757c, content=<a href='/topic/show?id=944315e85c0' target=_blank style='color:#2F92EE;'>#S-1#</a>, objectTitle=Gastric cancer：术前多西他赛联合顺铂加S-1治疗广泛淋巴结转移的胃癌的长期预后分析, objectType=article, longId=180606, objectId=a5e618060677, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a5e618060677, replyNumber=0, likeNumber=97, createdTime=2019-10-08, rootId=0, userName=ms3117646317107274, userId=a6477383481, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a5e618060677, moduleTitle=Gastric cancer：术前多西他赛联合顺铂加S-1治疗广泛淋巴结转移的胃癌的长期预后分析, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=a5e618060677)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 风湿免疫小助手

S-1

2020-05-29

ms3117646317107274 (审核中...)

前往app查看评论内容

#S-1#

EmPHasis-10 球囊血管成形术后慢性血栓栓塞性肺动脉高压的健康相关生活质量和运动能力

2022-09-06

ms3117646317107274 (审核中...)

前往app查看评论内容

#S-1#

J Autoimmunity：ETS-1通过上调CIRBP促进炎症性肠病中Th1细胞介导的黏膜炎症

2022-08-15

ms3117646317107274 (审核中...)

前往app查看评论内容

#S-1#

Oncologist: Apatinib（阿帕替尼）与S-1联合一线治疗晚期胃癌疗效和安全性

2021-12-02

ms3117646317107274 (审核中...)

前往app查看评论内容

#S-1#

Oncologist: Anlotinib（安罗替尼）联合S-1三线或后线治疗晚期NSCLC患者的疗效和安全性：II期临床研究

2021-12-01

ms3117646317107274 (审核中...)

前往app查看评论内容

#S-1#

J Thorac Oncol：Aumolertinib(HS-10296)治疗EGFR-T790M+晚期NSCLC患者的疗效和安全性：APOLLO研究

2021-11-29

ms3117646317107274 (审核中...)

前往app查看评论内容

#S-1#

Eur J Cancer：3期| 改良版FOLFIRINOX vs S-1方案二线治疗吉西他滨难治性转移性胰腺癌的疗效

2021-09-08

ms3117646317107274 (审核中...)

前往app查看评论内容

#S-1#

LANCET ONCOL：围手术期或术后辅助奥沙利铂联合S-1 vs术后辅助奥沙利铂联合卡培他滨在接受D2胃切除术的局部进展期胃或胃食管结合部腺癌患者的疗效和安全性(RESOLVE): 一项开放标签、优效性和非劣效的3期随机对照研究

2021-07-13

ms3117646317107274 (审核中...)

前往app查看评论内容

#S-1#

Cancers：放疗联合S-1治疗头颈部肿瘤的的疗效和安全性：来自Meta分析

2021-06-16

ms3117646317107274 (审核中...)

前往app查看评论内容

#S-1#

Nutrients：嗜酸乳杆菌DDS-1和乳酸双歧杆菌UABla-12可改善IBS患者的腹痛严重程度和症状

2021-02-01

ms3117646317107274 (审核中...)

前往app查看评论内容

#S-1#

Lancet oncol：S-1辅助治疗联合内分泌治疗用于ER+Her2-原发性侵袭性乳腺癌的疗效和安全性

2021-01-08

ms3117646317107274 (审核中...)

前往app查看评论内容

#S-1#

Br J Cancer：IRS-1介导ER+乳腺癌中PR驱动的干细胞性和内分泌抗性

2020-11-15

ms3117646317107274 (审核中...)

前往app查看评论内容

#S-1#

SLEEP 2020：AXS-12（reboxetine）治疗嗜睡症，II期试验结果即将揭晓

2020-08-31

ms3117646317107274 (审核中...)

前往app查看评论内容

#S-1#

靶向TROP2治疗药物DS-1062是NSCLC和乳腺癌的新星？

2020-08-10

ms3117646317107274 (审核中...)

前往app查看评论内容

#S-1#

抗体药物偶联物DS-1062研究范围被扩大，治疗晚期或转移性三阴性乳腺癌

2020-07-04

ms3117646317107274 (审核中...)

前往app查看评论内容

#S-1#

Cell Death Dis：mPGES-1/PGE2/MTDH轴调控T-ALL细胞生长

2020-04-21

ms3117646317107274 (审核中...)

前往app查看评论内容

#S-1#

Lancet oncol：TAS-102联合贝伐珠单抗可明显延长难治性转移性结直肠癌的无进展存活期

2020-02-03

ms3117646317107274 (审核中...)

前往app查看评论内容

#S-1#

ASCO 2020年度胃肠道癌专题讨论会：LONSURF和Futibatinib（TAS-120）的全新数据

2020-01-29

ms3117646317107274 (审核中...)

前往app查看评论内容

#S-1#

Sci tranl med：用GCase小分子调节剂（S-181）治疗帕金森病

2019-10-25

ms3117646317107274 (审核中...)

前往app查看评论内容

#S-1#

鞘内注射AVXS-101治疗2型SMA患者的STRONG试验取得阳性结果

2019-10-09

ms3117646317107274 (审核中...)

前往app查看评论内容

#S-1#

Gastric cancer：术前多西他赛联合顺铂加S-1治疗广泛淋巴结转移的胃癌的长期预后分析

2019-10-08

科室
- - 订阅+
  - 更多科室
工具
服务